Track topics on Twitter Track topics that are important to you
Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy
The post EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC appeared first on Pharmaceutical Business review.
Original Article: EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCCNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...